A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression
A 73-year-old male was initially treated with sorafenib for advanced stage HCC. However, the disease progressed 2 months after starting sorafenib. Progressive disease (PD) was confirmed by radiological examination, which revealed mediastinal and abdominal lymph node metastasis, pulmonary metastasis,...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-04-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/506331 |
id |
doaj-0fcced4907d2499581d62962eee01fac |
---|---|
record_format |
Article |
spelling |
doaj-0fcced4907d2499581d62962eee01fac2020-11-25T02:55:58ZengKarger PublishersCase Reports in Oncology1662-65752020-04-0113137938410.1159/000506331506331A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological ProgressionYoshiyuki WadaYuko TakamiTomoki RyuHiroki UreshinoHajime ImamuraShin SasakiHideki SaitsuA 73-year-old male was initially treated with sorafenib for advanced stage HCC. However, the disease progressed 2 months after starting sorafenib. Progressive disease (PD) was confirmed by radiological examination, which revealed mediastinal and abdominal lymph node metastasis, pulmonary metastasis, and intrahepatic recurrence. The patient was enrolled in the REACH-2 (NCT02435433) trial and randomized to receive ramucirumab (8 mg/kg div. every 2 weeks). The patient had a Child–Pugh score of 6A and his AFP level was found to be 1,256.8 ng/mL at initiation. Radiological examination revealed PD, 5 months after starting ramucirumab. Ramucirumab treatment was continued after the confirmation of radiological PD, not but clinical progression, as allowed by the study protocol. His AFP level increased after continuous ramucirumab treatment, however, it suddenly decreased from 7,653 ng/mL to within normal limits 10 months after initiation of ramucirumab treatment. Radiological evaluation revealed a significant decrease in the size of the tumors, which constituted a partial response (PR). We reported a rare case of advanced HCC with PR to a continuous ramucirumab treatment after radiological PD.https://www.karger.com/Article/FullText/506331ramucirumabhepatocellular carcinomalivermalignancyresponseprogressive disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yoshiyuki Wada Yuko Takami Tomoki Ryu Hiroki Ureshino Hajime Imamura Shin Sasaki Hideki Saitsu |
spellingShingle |
Yoshiyuki Wada Yuko Takami Tomoki Ryu Hiroki Ureshino Hajime Imamura Shin Sasaki Hideki Saitsu A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression Case Reports in Oncology ramucirumab hepatocellular carcinoma liver malignancy response progressive disease |
author_facet |
Yoshiyuki Wada Yuko Takami Tomoki Ryu Hiroki Ureshino Hajime Imamura Shin Sasaki Hideki Saitsu |
author_sort |
Yoshiyuki Wada |
title |
A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression |
title_short |
A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression |
title_full |
A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression |
title_fullStr |
A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression |
title_full_unstemmed |
A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression |
title_sort |
case of advanced hepatocellular carcinoma with partial response after continuous ramucirumab treatment beyond radiological progression |
publisher |
Karger Publishers |
series |
Case Reports in Oncology |
issn |
1662-6575 |
publishDate |
2020-04-01 |
description |
A 73-year-old male was initially treated with sorafenib for advanced stage HCC. However, the disease progressed 2 months after starting sorafenib. Progressive disease (PD) was confirmed by radiological examination, which revealed mediastinal and abdominal lymph node metastasis, pulmonary metastasis, and intrahepatic recurrence. The patient was enrolled in the REACH-2 (NCT02435433) trial and randomized to receive ramucirumab (8 mg/kg div. every 2 weeks). The patient had a Child–Pugh score of 6A and his AFP level was found to be 1,256.8 ng/mL at initiation. Radiological examination revealed PD, 5 months after starting ramucirumab. Ramucirumab treatment was continued after the confirmation of radiological PD, not but clinical progression, as allowed by the study protocol. His AFP level increased after continuous ramucirumab treatment, however, it suddenly decreased from 7,653 ng/mL to within normal limits 10 months after initiation of ramucirumab treatment. Radiological evaluation revealed a significant decrease in the size of the tumors, which constituted a partial response (PR). We reported a rare case of advanced HCC with PR to a continuous ramucirumab treatment after radiological PD. |
topic |
ramucirumab hepatocellular carcinoma liver malignancy response progressive disease |
url |
https://www.karger.com/Article/FullText/506331 |
work_keys_str_mv |
AT yoshiyukiwada acaseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT yukotakami acaseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT tomokiryu acaseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT hirokiureshino acaseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT hajimeimamura acaseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT shinsasaki acaseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT hidekisaitsu acaseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT yoshiyukiwada caseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT yukotakami caseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT tomokiryu caseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT hirokiureshino caseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT hajimeimamura caseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT shinsasaki caseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression AT hidekisaitsu caseofadvancedhepatocellularcarcinomawithpartialresponseaftercontinuousramucirumabtreatmentbeyondradiologicalprogression |
_version_ |
1724715102802804736 |